Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Brinavess
Vernakalant is an antiarrhythmic drug used to convert recent-onset atrial fibrillation to normal sinus rhythm. It's classified as an atrial-selective antiarrhythmic agent and works by blocking multiple potassium channels in the atria, thereby prolonging atrial refractoriness and slowing impulse conduction, promoting the restoration of sinus rhythm.
For the rapid conversion of recent-onset atrial fibrillation to sinus rhythm.
Outcome:
Increased risk of bradycardia and hypotension
Mechanism:
Additive effects on cardiac conduction
Outcome:
Additive bradycardia
Mechanism:
Synergistic negative chronotropic effects
Outcome:
Reduced vernakalant absorption
Mechanism:
Altered gastric pH
Most likely new formulation: Intravenous formulation with improved stability and reduced infusion time (Year: 2026, 60% confidence).
Based on current usage trends and clinical trial data, there is a 75% likelihood of vernakalant maintaining its current FDA approval status for atrial fibrillation conversion within the next 5 years.
Antiarrhythmic Agent
Benzamide Derivative